following a re-submission
agomelatine (Valdoxan®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of major depressive episodes in adults.
When used in a flexible dosing schedule, agomelatine significantly reduced the symptoms of depression and increased the number of patients who responded to treatment compared with
placebo. There are no comparative data from clinical studies with existing second line antidepressants using depression as the primary outcome.
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
The licence holder has indicated their intention to resubmit.
Download detailed advice135KB (PDF)
- Medicine name:
- agomelatine (Valdoxan) Resubmission
- SMC ID:
- Major depressive epsiodes in adults.
- Pharmaceutical company
- Servier Laboratories Ltd
- BNF chapter
- Central nervous system
- Submission type
- Not recommended
- Date advice published
- 13 September 2010